ABOUT MCG
McCloud Consulting Group was established by Dr Philip McCloud to be a world class Biometrics Contract Research Organisation (CRO). The quality of every company depends on its people; our employees have over 20 years international experience with global pharmaceutical and biotech companies.
In particular, MCG has extensive expertise in:
- working with global health authorities in designing development programs and in addressing health authority questions at the time of registration.
- serving as project or study biostatisticians for projects that have resulted in successful global approval of drug products for new indications.
- health economics with 10 years of pharmaceutical industry and senior management experience including the therapeutic areas of: oncology, infectious diseases, immunology, central nervous system disorders (schizophrenia, bipolar disorder, epilepsy), cardiovascular, endocrinology and substance abuse.
Our employees are enthusiastic team members working successfully with many clinical and study teams at the global and regional level. With a pragmatic approach and recognising the need to develop creative solutions to clinical trial design and sample size determinations, the MCG team is adept at balancing the scientific and budgetary requirements of clinical trials.
As a world class Biometrics CRO servicing Australia, Asia Pacific, and beyond, MCG can now deliver its international industry experience to your clinical trial.
MCG utilise award winning data management technology
Offering specialist advice in the management of your data, including: eCRF design, discrepancy resolution, laboratory data, and efficient data flow, MCG has chosen EVADO as its clinical database solution because of fast eCRF, and database creation times that save you time and expense.
MCG founder, Dr Philip McCloud
Dr. McCloud is an applied biostatistician with 35 years’ experience, including 13 years at the top levels of the pharmaceutical industry. Philip graduated from Flinders University, South Australia, with a BA (Hons) in Mathematical Statistics in 1976 and was employed as a Biometrician with the South Australian Department of Agriculture and Fisheries from 1975-1989. Philip went on to complete a PhD in 1987 on the Analysis of Categorical Repeated Measurements and Observer Agreement. As a lecturer at Monash University, Melbourne (1989-1997) Philip was also the Director of the Statistical Consulting Service. Within 3 years, the service had gained over 200 clients a year from the University research and medical community, Government, Industrial Companies, and collaborated with 15 Pharmaceutical companies.
Joining Roche in 1997 as the Inaugural Site Head of Biometrics in Sydney, Australia Philip’s brief was to build and develop a world class Biostatistics and Data management team to service Hoffman La Roche’s global drug development programs. This was soon achieved with outstanding results and included a team of 70 professionals under Philip’s management.
Philip was appointed Site Head of Pharma Development in Sydney in 2007.
Highlights of Philip’s time at Roche were his roles as Project Statistician for:
- Pegasys in Hepatitis B (1998-2010), which lead to global approval in 2005.
- Project Statistician for Xeloda in metastatic gastric cancer (MGC) (2000-2006).
- Herceptin in MGC (2005-2010).
Through these projects Philip has considerable experience discussing projects and answering questions from Global Health Authorities.